Neutrophil-to-lymphocyte ratio at 6 weeks post treatment in patients with advanced NSCLC was able to predict PFS after anti-PD-1/PD-L1 treatment [25]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.